trial · primary record
Cemiplimab
Non Small Cell Lung Cancer
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 184 |
| Primary completion | 2034-12-27 |
| Primary endpoint | Major Pathologic Response (MPR) rate as determined by central Blinded Independent Pathology Review (BIPR) |
| Registry ID | NCT06465329 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:57.054Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06465329
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cemiplimab · compound